Italia markets open in 7 hours 21 minutes

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
43,25-0,05 (-0,12%)
Alla chiusura: 03:44PM GMT

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 61 03 801 0
http://www.biotest.com

Settore/i
Settore
Impiegati a tempo pieno1.928

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Michael RamrothChairman of the Management Board, CEO & CFO1,21MN/D1961
Dr. Georg FloßCOO & Member of the Board of Management1,05MN/DN/D
Dr. Monika ButtkereitHead of Investor RelationsN/DN/DN/D
Dr. Christina ErbHead of Corp. HRN/DN/DN/D
Dr. Katrin BernösterHead of the Project Management OrganisationN/DN/DN/D
Mr. Peter SeithHead of Quality OperationsN/DN/DN/D
Dr. Jörg SchüttrumpfHead of R&DN/DN/DN/D
Dr. Wolfgang MöllerHead of Devel. - Plasma ProteinN/DN/DN/D
Dr. Hermann KeuperSr. VP of ManufacturingN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

Governance aziendale

L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.